Milestone Pharmaceuticals Inc (OQ:MIST)

Business Focus: Bio Therapeutic Drugs

Apr 17, 2024 08:00 am ET
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual...
Apr 08, 2024 11:36 am ET
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new clinical data demonstrating real-world application of etripamil,...
Apr 03, 2024 08:00 am ET
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET. The webcast is...
Apr 01, 2024 08:00 am ET
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology...
Mar 28, 2024 07:00 am ET
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food...
Mar 21, 2024 07:14 am ET
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update. “We look forward to resubmitting our NDA imminently. With the...
Feb 29, 2024 04:01 pm ET
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET. The webcast is...
Feb 29, 2024 07:00 am ET
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten...
Feb 28, 2024 04:37 pm ET
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering...
Feb 26, 2024 07:00 am ET
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT). Following the...
Jan 22, 2024 06:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Jan 18, 2024 09:00 pm ET
MILESTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Milestone Pharmaceuticals Inc. on Behalf of Milestone Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST) on behalf of Milestone stockholders. Our...
Jan 18, 2024 05:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Jan 18, 2024 01:23 pm ET
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about...
Jan 14, 2024 10:45 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Jan 10, 2024 04:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Jan 06, 2024 03:59 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) resulting from allegations that Milestone may have issued...
Jan 06, 2024 10:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
NEW YORK, Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Jan 02, 2024 03:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Jan 01, 2024 12:35 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) resulting from allegations that Milestone may have issued...
Dec 28, 2023 01:23 pm ET
Investigation Into Milestone Pharmaceuticals Inc. (MIST) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Milestone Pharmaceuticals Inc. (“Milestone Pharmaceuticals” or the “Company”) (NASDAQ: MIST) complied with federal securities laws.  On December 26, 2023, the Company disclosed it had received a Refusal...
Dec 28, 2023 10:02 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
NEW YORK, Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Dec 26, 2023 12:01 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) resulting from allegations that Milestone may have issued materially misleading business information to the investing public.
Dec 26, 2023 10:55 am ET
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about...
Dec 26, 2023 07:00 am ET
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray...
Nov 21, 2023 06:00 am ET
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 21, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.
Nov 21, 2023 06:00 am ET
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 21, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.
Nov 13, 2023 05:57 am ET
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /PRNewswire/ -- Milestone
Nov 13, 2023 05:57 am ET
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /CNW/ -- Milestone Pharmac
Nov 11, 2023 09:00 am ET
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placeboResults also showed statistically significant rapid and sustained reductions in ventricular rate and improvement in patient reported symptomsSafety and tolerability data were generally consistent with data from studies evaluating etripamil in PSVT Results support further clinical development in a Phase 3 clinical trial evaluating patient-administered etripamil for management
Nov 11, 2023 09:00 am ET
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p < 0.0001) compared to placeboResults also showed statistically significant rapid and sustained reductions in ventricular rate and improvement in patient reported symptomsSafety and tolerability data were generally consistent with data from studies evaluating etripamil in PSVT Results support further clinical development in a Phase 3 clinical trial evaluating patient-administered etripamil for management
Nov 07, 2023 06:00 am ET
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET. The webcast will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), which i
Nov 07, 2023 06:00 am ET
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET. The webcast will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR),
Oct 24, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVTComprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVTCARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable and at-the-ready option in the treatment of serious heart arrhythmias MO
Oct 24, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
Submission seeks approval for treatment of an abnormal heart rhythm, Paroxysmal Supraventricular Tachycardia or PSVTComprehensive data package includes positive results from pivotal Phase 3 RAPID trial which Company believes demonstrates new calcium channel blocker, etripamil, is twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVTCARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable and at-the-ready option in the treatment of serious heart arrhythmias MO
Oct 06, 2023 07:00 am ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Oct. 6, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires. 
Oct 06, 2023 07:00 am ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Oct. 6, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires. 
Sep 27, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023. Selected for a Featured Science Presentation, the ReVeRA study evaluated etripamil in emergency department patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The presentation will take place at the AHA Scientific Sessions in Philadelphia, PA and virtually from November 11-13, 2023.
Sep 27, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023. Selected for a Featured Science Presentation, the ReVeRA study evaluated etripamil in emergency department patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The presentation will take place at the AHA Scientific Sessions in Philadelphia, PA and virtually from November 11-13, 20
Sep 05, 2023 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 5, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 9:00 a.m. ET.
Aug 10, 2023 07:35 am ET
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
NDA submission for etripamil in patients with PSVT expected in October 2023Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with AFib-RVR Enrollment complete in Phase 2 ReVeRA study of etripamil in patients with AFib-RVR; topline data expected in fourth quarter of 2023MONTREAL and CHARLOTTE, N.C., Aug. 10, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the sec
Jun 20, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
-     Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
Jun 20, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
-     Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
Jun 01, 2023 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
MONTREAL and CHARLOTTE, N.C., June 1, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 a.m. ET.
Jun 01, 2023 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
MONTREAL and CHARLOTTE, N.C., June 1, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 a.m. ET.
May 22, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
-  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes
May 22, 2023 07:00 am ET
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
-  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes
May 11, 2023 07:16 am ET
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
-  NDA submission for etripamil in patients with PSVT currently on track for 3Q23
May 11, 2023 07:16 am ET
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
-  NDA submission for etripamil in patients with PSVT currently on track for 3Q23
May 08, 2023 07:00 am ET
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
-  Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD
May 08, 2023 07:00 am ET
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
-  Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD
Apr 12, 2023 07:00 am ET
Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 12, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 3:45 p.m. ET.
Apr 12, 2023 07:00 am ET
Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 12, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 3:45 p.m. ET.
Mar 29, 2023 09:17 am ET
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
-  Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025
Mar 29, 2023 09:17 am ET
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
-  Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025
Mar 28, 2023 07:00 am ET
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
-  Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 including etripamil NDA submission and launch in PSVT
Mar 28, 2023 07:00 am ET
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
-  Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 including etripamil NDA submission and launch in PSVT
Feb 28, 2023 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences:
Nov 29, 2022 06:00 am ET
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 29, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysma
Nov 29, 2022 06:00 am ET
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 29, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with pa
Nov 22, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 22, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.
Nov 22, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 22, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.
Nov 10, 2022 06:21 am ET
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-  Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil
Nov 10, 2022 06:21 am ET
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-  Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil
Nov 07, 2022 11:13 am ET
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to conversion was 17 minutes for patients treated with etripamil – three times faster than placeboAnalyses of pooled data show significant reductions in medical interventions and visits to the emergency department for patients who took etripamilSafety and tolerability data are consistent with previous trials, supporting potential self-administration of the optional repeat dose regimenMONTREAL and CHARLOTTE, N.
Nov 07, 2022 11:13 am ET
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) Median time to conversion was 17 minutes for patients treated with etripamil – three times faster than placeboAnalyses of pooled data show significant reductions in medical interventions and visits to the emergency department for patients who took etripamilSafety and tolerability data are consistent with previous trials, supporting potential self-administration of the optional repeat dose regimenMONTREAL and CHARLOTTE, N.
Oct 25, 2022 07:00 am ET
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the Americ
MONTREAL and CHARLOTTE, N.C., Oct. 25, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually. Etripamil, a n
Oct 25, 2022 07:00 am ET
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the Americ
MONTREAL and CHARLOTTE, N.C., Oct. 25, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually. Etripam
Oct 17, 2022 08:30 am ET
Thinking about buying stock in Archaea Energy, Agrify, Milestone Pharmaceuticals, Revlon, or Amyris?
NEW YORK, Oct. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LFG, AGFY, MIST, REV, and AMRS.
Oct 17, 2022 06:00 am ET
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
─     Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
Oct 17, 2022 06:00 am ET
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
─     Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
Sep 06, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.
Sep 06, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.
Aug 10, 2022 04:15 pm ET
Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-- Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study remains on track for mid-second half 2022
Aug 10, 2022 04:15 pm ET
Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-- Phase 3 RAPID study reached the target of 180 confirmed PSVT events treated with double-blind study medication required to initiate primary efficacy analysis; topline data readout for RAPID study remains on track for mid-second half 2022
Jun 02, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
MONTREAL and CHARLOTTE, N.C., June 2, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 1:30pm ET in New York, NY.
Jun 02, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
MONTREAL and CHARLOTTE, N.C., June 2, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 1:30pm ET in New York, NY.
May 27, 2022 05:03 pm ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., May 27, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone's common stock on May 16, 2022. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compen
May 27, 2022 05:03 pm ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., May 27, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone's common stock on May 16, 2022. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment
May 17, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
MONTREAL and CHARLOTTE, N.C., May 17, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
May 17, 2022 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
May 12, 2022 07:15 am ET
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-       RAPID topline data readout remains on track for mid-second half 2022
May 12, 2022 07:15 am ET
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
-       RAPID topline data readout remains on track for mid-second half 2022
Apr 30, 2022 09:00 am ET
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention -
Apr 30, 2022 09:00 am ET
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention -
Apr 15, 2022 04:41 pm ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., April 15, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted one new employee 65,000 incentive stock options at a per share exercise price of $6.85, the closing price of Milestone's common stock on April 1, 2022 and another new employee 36,000 incentive stock options at a per share exercise price of $6.93, the closing price of Milestone's common stock on April 11, 2022. The
Apr 15, 2022 04:41 pm ET
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., April 15, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Milestone's Compensation Committee granted one new employee 65,000 incentive stock options at a per share exercise price of $6.85, the closing price of Milestone's common stock on April 1, 2022 and another new employee 36,000 incentive stock options at a per share exercise price of $6.93, the closing price of Milestone's common stock on April 11, 202
Apr 14, 2022 07:00 am ET
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MDConference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ETMONTREAL and CHARLOTTE, N.C., April 14, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET. The event will focus on etripamil, the Company's lead investigational product, for
Apr 14, 2022 07:00 am ET
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MDConference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ETMONTREAL and CHARLOTTE, N.C., April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET. The event will focus on etripamil, the Company's lead investigational produc
Mar 24, 2022 07:20 am ET
Mar 24, 2022 07:20 am ET
Mar 01, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., March 1, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following investor conferences:
Mar 01, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., March 1, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of management will present at the following investor conferences:
Feb 16, 2022 06:00 am ET
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of global drug development and clinical experience across a range of therapeutic areas, with a focus on cardiovascular medicine. He will replace Francis Plat, M.D., wh
Feb 16, 2022 06:00 am ET
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of global drug development and clinical experience across a range of therapeutic areas, with a focus on cardiovascular medicine. He will replace Francis Plat, M.D., who will
Jan 04, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022.
Jan 04, 2022 06:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022.
Nov 15, 2021 06:00 am ET
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR –
Nov 15, 2021 06:00 am ET
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR –
Nov 12, 2021 06:20 am ET
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.
Nov 12, 2021 06:20 am ET
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.
Nov 11, 2021 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 11, 2021 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Sep 22, 2021 07:00 am ET
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.
Sep 07, 2021 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.
Sep 07, 2021 07:00 am ET
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.
Aug 11, 2021 04:18 pm ET
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.
Aug 11, 2021 04:18 pm ET
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.
May 26, 2021 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 26, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET. The conference will be held in a virtual meeting format.
May 17, 2021 07:02 am ET
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial -
May 17, 2021 07:01 am ET
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.
May 17, 2021 07:00 am ET
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China.  Ji Xing is a biotechnology company headquartered in Shanghai and backed by R
Mar 29, 2021 05:32 pm ET
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update.
Mar 29, 2021 05:30 pm ET
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), or the ReVeRA study.
Feb 25, 2021 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Feb 25, 2021 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 23, 2020 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 23, 2020 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 18, 2020 06:00 am ET
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT –
Nov 18, 2020 06:00 am ET
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT –
Nov 13, 2020 06:00 am ET
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update.
Nov 13, 2020 06:00 am ET
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update.
Nov 11, 2020 06:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 AM ET. The conference will be held in a virtual meeting format.
Nov 11, 2020 06:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Nov. 11, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 AM ET. The conference will be held in a virtual meeting format.
Oct 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share. The public offering price of each common share is $5.25 and the public offerin
Oct 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share. The public offering price of each common share is $5.25 and the public
Oct 22, 2020 04:01 pm ET
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it intends to offer and sell common shares and, to certain investors in lieu thereof, pre-funded warrants to purchase common shares, in an underwritten public offering. All of the securities in the offering will be sold by Milestone. The offering is subject to market and other conditions, and there can be no assurance as
Oct 22, 2020 04:01 pm ET
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it intends to offer and sell common shares and, to certain investors in lieu thereof, pre-funded warrants to purchase common shares, in an underwritten public offering. All of the securities in the offering will be sold by Milestone. The offering is subject to market and other conditions, and there can be no assura
Sep 22, 2020 07:00 am ET
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board. 
Sep 08, 2020 07:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Sept. 8, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Aug 12, 2020 07:00 am ET
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2020 and provided a clinical and corporate update.
Aug 06, 2020 07:00 am ET
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
MONTREAL and CHARLOTTE, N.C., Aug. 6, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 PM ET. The conference will be held in a virtual meeting format.
Aug 06, 2020 07:00 am ET
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
MONTREAL and CHARLOTTE, N.C., Aug. 6, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 PM ET. The conference will be held in a virtual meeting format.
Jul 24, 2020 09:31 am ET
Thinking about buying stock in Arbutus Biopharma, Polarityte Inc, Milestone Pharmaceuticals, Vonage, or BioNano Genomics?
NEW YORK, July 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, PTE, MIST, VG, and BNGO.
Jul 23, 2020 10:35 am ET
Thinking about buying stock in Milestone Pharmaceuticals, Advanced Micro Devices, CymaBay Therapeutics, Pfizer Inc, or AT&T?
NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MIST, AMD, CBAY, PFE, and T.
Jul 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces $25 Million Private Placement
MONTREAL and CHARLOTTE, N.C., July 23, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a securities purchase agreement with affiliates of an existing shareholder, RTW Investments, LP, for a $25 million private placement. The private placement is expected to close on or about July 24, 2020, subject to the satisfaction of customary closing conditions.
Jul 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces $25 Million Private Placement
MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a securities purchase agreement with affiliates of an existing shareholder, RTW Investments, LP, for a $25 million private placement. The private placement is expected to close on or about July 24, 2020, subject to the satisfaction of customary closing conditions.
Jul 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of <0.05) -
Jul 23, 2020 07:00 am ET
Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
- Recently completed NODE-301 and ongoing NODE-301B studies can be used as two efficacy studies supporting a future NDA submission (target p-values of <0.05) -
May 27, 2020 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 27, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 8:30 AM ET. The conference will be held in a virtual meeting format.
May 27, 2020 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 27, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 8:30 AM ET. The conference will be held in a virtual meeting format.
May 14, 2020 07:15 am ET
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update.
May 14, 2020 07:15 am ET
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update.
Mar 23, 2020 11:08 pm ET
Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, March 23, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Milestone Pharmaceuticals Inc. (NASDAQ: MIST) ("Milestone or the "Company") for violations of federal securities laws.
Mar 23, 2020 04:05 pm ET
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
– Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) –
Mar 23, 2020 04:05 pm ET
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
– Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) –
Mar 06, 2020 06:00 am ET
Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update
– Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month – 
Nov 14, 2019 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 14, 2019 06:00 am ET
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
Nov 13, 2019 06:00 am ET
Nov 13, 2019 06:00 am ET
Oct 03, 2019 07:00 am ET
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company's open-label, global safety study of etripamil, the Company's novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).
Oct 03, 2019 07:00 am ET
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company's open-label, global safety study of etripamil, the Company's novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).
Sep 10, 2019 07:00 am ET
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development. Mr. Hasija brings to Milestone two decades of experience in corporate finance and business development within the healthcare industry.
Sep 10, 2019 07:00 am ET
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development. Mr. Hasija brings to Milestone two decades of experience in corporate finance and business development within the healthcare industry.
Aug 13, 2019 07:00 am ET
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
- FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies -
Aug 13, 2019 07:00 am ET
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
- FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies -
Aug 06, 2019 07:00 am ET
Milestone Pharmaceuticals to Host Mid-Year Update Conference Call
MONTREAL and CHARLOTTE, N.C., Aug. 6, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it will host a mid-year update conference call on Tuesday, August 13, 2019 at 8:00 a.m. Eastern Time.
Aug 06, 2019 07:00 am ET
Milestone Pharmaceuticals to Host Mid-Year Update Conference Call
MONTREAL and CHARLOTTE, N.C., Aug. 6, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that it will host a mid-year update conference call on Tuesday, August 13, 2019 at 8:00 a.m. Eastern Time.
Jul 16, 2019 07:32 am ET
Pappas Capital Expands Leadership Team With Appointments Of Kyle Rasbach To Managing Partner And Matthew Boyer To Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C., July 16, 2019 /PRNewswire/ -- Pappas Capital, a leading investor in early-stage life sciences companies, today announced the promotion of Kyle Rasbach, PhD, PharmD to a Managing Partner of Pappas Ventures, the firm's venture capital business. In his new role, Dr. Rasbach will help to oversee Pappas Ventures and lead fundraising and investment efforts for its future venture funds. Pappas Capital also announced that Matthew Boyer has been named Chief Financial Officer, succeeding Ford Worthy who will continue with the firm as a Partner and Senior Advisor.
May 30, 2019 07:00 am ET
Milestone Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 30, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced Joseph G. Oliveto, President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York on Thursday, June 6, 2019 at 9:30 a.m. Eastern Time.
May 21, 2019 04:05 pm ET
Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting
MONTREAL and CHARLOTTE, N.C., May 21, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the presentation of data on the economic impact of paroxysmal supraventricular tachycardia (PSVT) and current standard of care therapy at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting.
May 21, 2019 04:05 pm ET
Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting
MONTREAL and CHARLOTTE, N.C., May 21, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the presentation of data on the economic impact of paroxysmal supraventricular tachycardia (PSVT) and current standard of care therapy at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting.
May 14, 2019 06:40 pm ET
Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 14, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the underwriters for its initial public offering of common shares have fully exercised their option to purchase an additional 825,000 common shares at the public offering price of $15.00 per share. The gross proceeds to Milestone from the exercise of the option, are expected to be approximately $12.4 million, bringing the
May 14, 2019 06:40 pm ET
Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the underwriters for its initial public offering of common shares have fully exercised their option to purchase an additional 825,000 common shares at the public offering price of $15.00 per share. The gross proceeds to Milestone from the exercise of the option, are expected to be approximately $12.4 million, bringi
May 13, 2019 04:05 pm ET
Milestone Pharmaceuticals Announces Closing of Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 13, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.  The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, were approximately $82.5 million. All of the common shares were offered b
May 13, 2019 04:05 pm ET
Milestone Pharmaceuticals Announces Closing of Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the closing of its previously announced initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.  The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, were approximately $82.5 million. All of the common shares were of
May 08, 2019 11:02 pm ET
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 8, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.  The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $82.5 million. All of the common shares are being offe
May 08, 2019 11:02 pm ET
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
MONTREAL and CHARLOTTE, N.C., May 8, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.  The gross proceeds to Milestone, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $82.5 million. All of the common shares are bei

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.